{
    "id": 30516,
    "fullName": "QKI - RAF1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "QKI-RAF1 results from the fusion of QKI and RAF1, which leads to increased Erk signaling and an ability to homodimerize and form heterodimers with wild-type BRAF, CRAF and QKI in cell culture, results in increased colony and tumor formation in animal models, and demonstrates resistance to first and second generation RAF inhibitors in culture (PMID: 30517658, PMID: 28806393). QKI-RAF1 has been identified in pleomorphic xanthoastrocytoma (PMID: 30517658).",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                },
                {
                    "id": 15707,
                    "pubMedId": 30517658,
                    "title": "Spinal Pleomorphic Xanthoastrocytoma With a QKI-RAF1 Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30517658"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 9444,
        "geneSymbol": "QKI",
        "terms": [
            "QKI",
            "Hqk",
            "hqkI",
            "QK",
            "QK1",
            "QK3"
        ]
    },
    "variant": "QKI - RAF1",
    "createDate": "07/16/2019",
    "updateDate": "08/27/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5894,
                "geneSymbol": "RAF1",
                "terms": [
                    "RAF1",
                    "c-Raf",
                    "CMD1NN",
                    "CRAF",
                    "NS5",
                    "Raf-1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 18434,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited MAPK and PI3K signaling, resulted in inhibition of soft agar growth in transformed cells expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18438,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited Erk phosphorylation and soft agar growth in transformed cells expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18440,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation and soft agar growth in transformed mouse astrocytes expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18430,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 treatment results in increased soft agar growth of transformed mouse astrocytes expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18443,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Afinitor (everolimus) combination treatment inhibited MAPK and PI3K signaling, resulted in suppression of soft agar growth in transformed cells expressing QKI-RAF1 in culture, and prolonged tumor suppression in xenograft models (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1271,
                "therapyName": "Everolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited MAPK and PI3K signaling, resulted in inhibition of soft agar growth in transformed mouse astrocytes expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18445,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Afinitor (everolimus) combination treatment inhibited MAPK and PI3K signaling, resulted in suppression of soft agar growth in transformed mouse astrocytes expressing QKI-RAF1 in culture, and prolonged tumor suppression in xenograft models (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1271,
                "therapyName": "Everolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18439,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation and soft agar growth in transformed cells expressing QKI-RAF1 in culture, but only delayed tumor growth in xenograft models (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18431,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 treatment results in increased soft agar growth of transformed mouse astrocytes expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18426,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 treatment resulted in paradoxical activation of the MAPK pathway and increased soft agar growth in transformed cells expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18427,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 treatment resulted in paradoxical activation of the MAPK pathway and increased soft agar growth in transformed cells expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32710,
            "profileName": "QKI - RAF1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}